Viriom Overview

  • Founded
  • 2009
  • Status
  • Private
  • Employees
  • 4
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $4.7M
Latest Deal Amount
  • Investors
  • 3

Viriom General Information


Developer of a biotechnology platform designed to focus on pharmaceuticals for treating certain viruses. The company's platform offers affordable therapies against life-threatening infections such as HIV (human immunodeficiency virus) and Hepatitis B virus and has developed a proprietary pre-clinical lead compound as a potentially curative treatment of chronic HBV, enabling physicians to treat their patients in an enhanced way.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Other Industries
Primary Office
  • 12760 High Bluff Drive
  • Suite 370
  • San Diego, CA 92130
  • United States
+1 (858) 000-0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Viriom Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Later Stage VC 11-May-2016 $4.7M 00.000 Completed Generating Revenue
1. Early Stage VC Completed Startup
To view Viriom’s complete valuation and funding history, request access »

Viriom Comparisons

HQ Location
Total Raised
Post Valuation
Last Financing Details
Developer of a biotechnology platform designed to focus on pharmaceuticals for treating certain viruses. The company's p
San Diego, CA
4 As of 2016
0000000000 0 00.000


olore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliqu
Framingham, MA
0 As of 0000
000000000 000.00


ion ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit
Mountain View, CA
000 As of 0000
000000 - 000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Viriom Competitors (37)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Xenetic Bioscience Corporation Framingham, MA 0 000.00 000000000 000.00
000000000000 Formerly VC-backed Mountain View, CA 000 00000 000000 - 000 00000
000000000 00000000 Formerly VC-backed Charlottesville, VA 00 000.00 00000000 000.00
0000000 Formerly Angel backed Vancouver, WA 00 00000 000000000 00000
00000000 Formerly VC-backed Sunnyvale, CA 0 00.000 00000000000 00.000
You’re viewing 5 of 37 competitors. Get the full list »

Viriom Executive Team (7)

Name Title Board Seat Contact Info
Ronald Demuth Board Member & Chief Financial Officer
Robert Murphy MD Advisor & CMO
Vladimir Kan Ph.D CBO
Oleg Korzinov Board Member & Vice President, Development
Iain Dukes Ph.D Chief Executive Officer
You’re viewing 5 of 7 executive team members. Get the full list »

Viriom Board Members (7)

Name Representing Role Since
Augustine Lawlor Viriom Board Member 000 0000
Jennifer Cayer Viriom Board Member 000 0000
Milos Petrovic Viriom Board Member & Scientific Advisor 000 0000
Nikolay Merkin Self Board Member 000 0000
Nikolay Savchuk Ph.D Torrey Pines Investment Chairman & Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Viriom Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Viriom Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
ChemRar High Tech Center Corporation Minority 000 0000 000000 0
Skolkovo Foundation Limited Partner 000 0000 000000 0
Torrey Pines Investment Venture Capital Minority 000 0000 000000 0
To view Viriom’s complete investors history, request access »